Research Desk Line-up: Nordson Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Zebra Technologies Corp. (NASDAQ: ZBRA), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ZBRA, following the Company’s disclosure of its second quarter financial results on August 08, 2017. The producer of printers for bar codes, plastic cards, and radio-frequency identification tags outperformed top- and bottom-line expectations. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Diversified Machinery industry. Pro-TD has currently selected Nordson Corporation (NASDAQ: NDSN) for due-diligence and potential coverage as the Company reported on August 21, 2017, its financial results for Q3 FY17. Register for a free membership today, and be among the early birds that get access to our report on Nordson when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ZBRA; also brushing on NDSN. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=ZBRA

http://protraderdaily.com/optin/?symbol=NDSN

Earnings Reviewed

Zebra Technologies’ net sales were $896 million in Q2 2017 compared to $879 million in Q2 2016. The Company’s revenue numbers exceeded analysts’ expectations of $874.8 million.

For Q2 2017, Zebra Technologies’ gross profit totaled $411 million compared to $406 million in the prior year’s corresponding period. The Company’s adjusted gross margin was 46.0% for the reported quarter compared to 46.4% in the prior year’s same period. The decrease was primarily due to changes in business mix. Zebra Technologies’ adjusted operating expenses decreased to $274 million in Q2 2017 from $282 million in Q2 2016; reflecting the company’s continued focus on improving operating efficiency, controlling expenses, and the divestiture of the wireless LAN business.

Zebra Technologies’ net income was $17 million, or $0.32 per diluted share, for Q2 2017 compared to a net loss of $45 million, or ($0.88) per diluted share, for Q2 2016. The Company’s non-GAAP net income was $80 million, or $1.51 per diluted share, for the reported quarter compared to $59 million, or $1.17 per diluted share, for the year ago corresponding period. Zebra Technologies’ earnings beat Wall Street’s expectations of $1.45 per share.

For Q2 2017, Zebra Technologies’ adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) was $159 million, or 17.7% of adjusted net sales, compared to $144 million, or 16.3% of adjusted net sales, for Q2 2016. This was primarily due to higher gross profit and lower operating expenses.

Sales Details

Zebra Technologies’ consolidated adjusted net sales were $897 million in Q2 2017 compared to $882 million in Q2 2016. The Company’s consolidated organic net sales growth for the reported quarter was 6.4%; reflecting growth across all regions, most notably North America and Latin America.

During Q2 2017, Zebra Technologies net sales in the Enterprise segment were $584 million compared to $577 million in Q2 2016. The Company’s Legacy Zebra segment’s net sales were $313 million in the reported quarter versus $305 million in the prior year’s comparable quarter. In Q2 2017, Zebra Technologies’ organic net sales grew 7.9% on a y-o-y basis in the Enterprise segment and 3.7% in the Legacy Zebra segment.

Balance Sheet and Cash Flow

As of July 01, 2017, Zebra Technologies had cash and cash equivalents of $95 million and total long-term debt of $2.4 billion.

The Company’s free cash flow was $181 million in H1 2017. Zebra Technologies generated $203 million and incurred capital expenditure of $22 million. During H1 2017, the Company made $240 million in term loan payments and $70 million in scheduled cash interest payments.

Outlook

For Q3 2017, Zebra Technologies is forecasting adjusted net sales to change approximately (1) % to 2% from adjusted net sales of $906 million in Q3 2016. The Company expects organic net sales growth of approximately 2% to 5% in the upcoming quarter.

For Q3 2017, Zebra Technologies is forecasting adjusted EBITDA margin to be approximately 18% to 19%, favorable to the prior year’s same period. Non-GAAP earnings per diluted share are expected to be in the range of $1.65 to $1.85, assuming an effective tax rate in the low- to mid-20% range for the upcoming quarter.

For FY17, Zebra Technologies is anticipating 3% to 6% organic net sales growth, which is at the higher end of its prior outlook. The Company expects adjusted EBITDA margin to be in the band of 18% to 19% for the full year 2017; an improvement compared to the full year 2016. For the full year 2017, Zebra Technologies expects to make debt principal payments totaling at least $300 million.

Stock Performance

On Tuesday, August 29, 2017, the stock closed the trading session at $101.59, dropping 1.20% from its previous closing price of $102.82. A total volume of 272.27 thousand shares have exchanged hands. Zebra Technologies’ stock price soared 11.99% in the past six months and 42.70% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 18.46%. The stock currently has a market cap of $5.38 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474156

NEW YORK, NY / ACCESSWIRE / August 30, 2017 / Grupo Aval Acciones y Valores SA (NYSE: AVAL) will be discussing their earnings results in their Q2 Earnings Call to be held August 30, 2017 at 10:00 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/2770.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/2770.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 474178

Research Desk Line-up: Cabela’s Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Acushnet Holdings Corp. (NYSE: GOLF) (“Acushnet”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=GOLF, following the Company’s announcement of its second quarter financial results on August 11, 2017. The golf products maker updated its outlook for 2017. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Sporting Goods Stores industry. Pro-TD has currently selected Cabela’s Incorporated (NYSE: CAB) for due-diligence and potential coverage as the Company reported on August 03, 2017, its financial results for Q2 FY17. Register for a free membership today, and be among the early birds that get access to our report on Cabela’s when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on GOLF; also brushing on CAB. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=GOLF

http://protraderdaily.com/optin/?symbol=CAB

Earnings Reviewed

For the three months ended June 30, 2017, Acushnet recorded net sales of $428.0 million, down 7.6% compared to net sales of $463.3 million in Q2 2016. The Company’s sales declined 6.6% in a constant currency. Acushnet’s net sales fell short of analysts’ expectations of $463.7 million

Acushnet’s consolidated net sales decline in the reported quarter was attributed to several factors, primarily in the United States. These factors include the ongoing effects of the reduced US store count and retail consolidation, unfavorable weather conditions, and promotional activity by competitors. The Company’s consolidated net sales in the United States decreased by 8.5% in Q2 2017. Acushnet posted a y-o-y decline in net sales in regions outside the United States of 6.6%, down 4.5% on a constant currency basis, with Korea up 7.5%, offset by Japan down 13.4% and Europe, Middle-East, and Africa (EMEA) declining 3.4%.

During Q2 2017, net income attributable to Acushnet had improved to $33.02 million, or $0.44 per diluted share, compared to net income of $27.06 million, or $0.39 per diluted share, in Q2 2016, primarily due to lower interest expense and other expense, partially offset by lower income from operations. The Company’s net income lagged behind Wall Street’s expectations of $0.55 per share.

Acushnet’s adjusted EBITDA was $71.8 million for Q2 2017, down 13.5% compared to adjusted EBITDA of $83.0 million in Q2 2016. The Company’s adjusted EBITDA margin was 16.8% for the reported quarter versus 17.9% for the prior year’s same period.

Acushnet’s Segment Results

During Q2 2017, the Titleist golf balls’ net sales totaled $154.96 million, down 6.6%, or 5.6% in a constant currency, as a result of a sales volume decline in both the ProV1 franchise and the performance models, the latter of which are in their second year of their two-year product life cycle.

The Company’s Titleist golf clubs’ net sales were $93.34 million compared to net sales of $118.34 million in the year ago corresponding period, due to lower sales volumes, primarily in the iron series, Scotty Cameron Select putters, and Vokey Design wedges, all of which are in the second year of their two-year product lifecycle. This decrease was partially offset by an increase in average selling prices across all product categories, in particular the new 917 model drivers and fairways.

The Titleist golf gear’s net sales increased 5.6% to $47.30 million, or 6.3% on a constant currency, primarily due to higher average selling prices across all categories of the gear business. The Company’s net sales from FootJoy golf wear declined 5.8% to $112.50 million, primarily due to a sales volume decline in the footwear and glove categories.

Cash Dividend

Acushnet’s Board of Directors declared a quarterly cash dividend in an amount of $0.12 per share of common stock. The dividend will be payable on September 15, 2017, to stockholders of record on September 01, 2017.

Outlook

For FY17, Acushnet is forecasting consolidated net sales to be in the range of $1.545 billion to $1.565 billion. The Company’s consolidated net sales, on a constant currency basis, are expected to be in the range of a decrease of 0.7% to an increase of 0.6% in 2017. Acushnet’s adjusted EBITDA is expected to be in the range of $220 million to $230 million in 2017.

Stock Performance

At the close of trading session on Tuesday, August 29, 2017, Acushnet’s stock price slightly fell 0.95% to end the day at $16.76. A total volume of 249.28 thousand shares were exchanged during the session. The Company’s shares are trading at a PE ratio of 28.80 and have a dividend yield of 2.86%. At Tuesday’s closing price, the stock’s net capitalization stands at $1.23 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474157

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily takes a closer look at Apple Hospitality REIT, Inc. (NYSE: APLE) (“Apple Hospitality”) as the Company’s stock will begin trading ex-dividend on August 31, 2017. In order to capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on August 30, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on APLE. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=APLE

Dividend Declared

On August 22, 2017, Apple Hospitality REIT announced that its Board of Directors declared a regular monthly cash distribution of $0.10 per common share for the month of September 2017. The distribution is payable on September 18, 2017, to shareholders of record as of September 05, 2017.

Apple Hospitality REIT’s indicated dividend represents a yield of 6.71%, which is substantially above the average dividend yield for the financial sector of 3.31%. The Company has raised its dividend for one year.

Dividend Insights

Apple Hospitality currently has a dividend payout ratio of 69.0%, which indicates that the Company distributes approximately $0.69 for every $1.00 earned. The dividend payout ratio reflects how much money a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts’ estimates, Apple Hospitality is forecasted to report earnings of $0.99 versus the Company’s annualized dividend of $1.20. Apple Hospitality is a Real Estate Investment Trust (REIT). REITs are structured by law to distribute at least 90% of earnings. Moreover, since REITs generate income from owning portfolios of investment in real estate, they are likely to have higher depreciation charges.

Since depreciation is a non-cash charge, it does not directly impact the ability of dividend the companies can distribute. For this reason, Fund from Operations (FFO) is calculated by adding depreciation and amortization to earnings and subtracting any gains on sales, and this provides a better picture of a company’s profitability and capacity to pay and sustain dividends. For instance, for the quarter ended June 30, 2017, net income available to Apple Hospitality’s common shareholders was $87.61 million, or $0.39 per share, while the Company’s modified FFO from operations was $113.65 million, or $0.51 per diluted share, which should sufficiently cover the dividend payout.

As of June 30, 2017, Apple Hospitality’s total assets were worth $4.90 billion compared to total liabilities of $1.40 billion. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development for Apple Hospitality

On August 08, 2017, Apple Hospitality announced net income for the quarter ended June 30, 2017 of $87.61 million, or $0.39 per share, with net income surging 60.1% compared to net income of $54.72 million, or $$0.31per share, for Q2 2016.

Apple Hospitality completed the sale of its 224-room Hilton® hotel in Dallas, Texas, on April 20, 2017, for a gross sales price of approximately $56 million, including debt assumed by the buyer of approximately $27 million. As a result of the sale, the Company recognized a gain of approximately $16 million during the second quarter of 2017.

In June 2017, the Company entered into a contract for the sale of its 316-room Marriott® hotel in Fairfax, Virginia for a gross sales price of $42 million. The contract is subject to a number of conditions to closing, therefore, there can be no assurance that a closing will occur. If closing conditions are met, it is anticipated that the sale would be completed by the end of 2017. The Company currently estimates a gain on sale of approximately $1 million if the deal is finalized.

Capital Improvements

Apple Hospitality consistently reinvests in its hotels to maintain and enhance each property’s relevance and competitive position within its respective market. During the six months ended June 30, 2017, the Company invested approximately $24 million in capital expenditures. The Company plans to continue to reinvest in its hotels and anticipates investing an additional $35 million to $45 million in capital improvements during the remainder of 2017, which includes various scheduled renovation projects for approximately 15 to 20 properties.

About Apple Hospitality REIT, Inc.

Apple Hospitality REIT is a publicly traded REIT that owns one of the largest portfolios of upscale, select-service hotels in the United States. The Company’s portfolio consists of 235 hotels, with approximately 30,000 guestrooms, diversified across the Hilton® and Marriott® families of brands with locations in urban, high-end suburban and developing markets throughout 33 states.

Stock Performance

At the close of trading session on Tuesday, August 29, 2017, Apple Hospitality REIT’s stock price rose slightly by 0.34% to end the day at $17.81. A total volume of 762.22 thousand shares were exchanged during the session. The Company’s shares are trading at a PE ratio of 22.12 and have a dividend yield of 6.74%. At Tuesday’s closing price, the stock’s net capitalization stands at $3.97 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474158

Research Desk Line-up: Transcontinental Realty Investors Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Colony NorthStar, Inc. (NYSE: CLNS), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=CLNS. Colony NorthStar, Inc. (NYSE: CLNS) and some of its affiliates, NorthStar Real Estate Income Trust, Inc. (NorthStar I), a public, non-traded REIT, and NorthStar Real Estate Income II, Inc. (NorthStar II), a public, non-traded REIT, announced on August 28, 2017 that the three Companies have signed a tri-party agreement wherein a select portfolio of Colony NorthStar assets and liabilities (CLNS Contributed Portfolio) will merge with NorthStar I and NorthStar II. The all – stock merger transaction will lead to the formation of a leading commercial real estate credit REIT with approximately $5.5 billion in assets and $3.4 billion in equity value. The merged Company has been named as Colony NorthStar Credit Real Estate, Inc. (CNCRE). For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the REIT – Diversified industry. Pro-TD has currently selected Transcontinental Realty Investors, Inc. (NYSE: TCI) for due-diligence and potential coverage as the Company reported on August 14, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Transcontinental Realty Investors when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CLNS; also brushing on TCI. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=CLNS

http://protraderdaily.com/optin/?symbol=TCI

Details of the transaction

According to the merger agreement, Colony NorthStar and some of its affiliates will contribute the CLNS Contributed Portfolio, which includes Colony NorthStar’s substantially all the US investments in the Other Equity and Debt segment that are transferable assets consistent with the CNCRE’s strategy (CLNS Contributions) plus NorthStar I and NorthStar II will merge with and into the CNCRE. After which only CNCRE will continue to exist.

After the completion of the merger, Colony NorthStar will receive both shares of Class A common stock of CNCRE and membership units in the CNCRE’s operating Company against the value of CLNS’ Contributed Portfolio. Units in the CNCRE’s operating Company will be exchangeable against CNCRE’s Class A common stock or cash at CNCRE’s discretion. All Class A common stock received by Colony NorthStar against its CLNS Contributed Portfolio or by way of exchange against units in the CNCRE’s operating Company come with a lock-in period. During the lock-in period, Colony NorthStar would be prohibited from selling the Class A common stock of CNCRE for one year from the date of closing of the transaction.

Shareholders of NorthStar I and NorthStar II will receive CNCRE’s Class B common stock. Shareholders of NorthStar I and NorthStar II will be able to convert CNCRE’s Class B common stock into CNCRE’s Class A common stock as per the schedule mentioned below:

10% within 30 days from the date of closing of the transaction;
45% at 180 days from the date of closing of the transaction;
45% at 1 year from the date of closing of the transaction.

CLNS Contributions are expected to be tax-free for Colony NorthStar, and NorthStar I and NorthStar II mergers would also qualify as tax-free reorganizations.

The transaction has been approved by the Board of Directors of Colony NorthStar as well as NorthStar I and NorthStar II’s special committees and Board of Directors. The transaction is expected to close in Q4 2017 or Q1 2018 subject to regulatory and shareholders’ approvals and other closing conditions. The closing of the transaction is also based on the successful listing of CNCRE’s stock on a national securities exchange, which could take around nine months’ time after the transaction is approved by the shareholders of NorthStar I and NorthStar II.

Arrangement Post the completion of transaction

Once the merger is completed, Colony NorthStar will be the largest single investor in CNCRE and own approximately 37% stake. Shareholders of NorthStar I will own approximately 32% stake and shareholders of NorthStar II will own approximately 31% stake in CNCRE. The percentage of ownership stake is subject to certain adjustments as per the terms of the merger agreement.

Post the completion of the merger, Colony NorthStar will enter into a management agreement with CNCRE on market terms to serve as CNCRE’s external manager. Kevin P. Traenkle, Colony NorthStar’s current Executive Vice President and Chief Investment Officer, is expected to be the CEO, and Sujan Patel, Colony NorthStar’s current Managing Director and Co-Head of US Investment Management, is expected to be the CFO of CNCRE. CNCRE’s new Board of Directors is expected to have seven members out of which four would be independent directors.

Strategic and Financial Advantages

The merger is expected to offer numerous strategic and financial advantages to all the stakeholders of all three parties of the merger – Colony NorthStar, NorthStar I, and NorthStar II. The merger will create CNCRE – a leading commercial real estate credit REIT (Real Estate Investment Trust), with approximately $5.5 billion in assets and $3.4 billion in equity value. CNCRE will be the second largest publicly listed commercial mortgage REIT, by equity value.

CNCRE will have a well-diversified and stabilized investments portfolio with attractive in-place yield and potential for capital appreciation and net asset value growth via equity participations and owned real estate.

Colony NorthStar, being the majority stakeholder in CNCRE, brings with it a rich asset management experience across the capital stack through multiple real estate cycles. This will allow Colony NorthStar to align its interests with CNCRE’s stockholders.

CNCRE will have diversified investment criteria across its capital structure. This will allow CNCRE to mitigate reinvestment risk and provide flexibility through economic cycles and achieve appropriate risk-adjusted returns.

CNCRE would have access to multiple financing sources to raise capital at attractive costs including credit facilities, credit market securitizations, mortgage debt on real estate and term facilities.

About parties to the merger agreement

Los Angeles, California based Colony NorthStar, Inc. is a leading global real estate and investment management firm. It is a diversified equity REIT with an embedded institutional and retail investment management business. The Company was formed as a result of the merger between Colony Capital, Inc., NorthStar Asset Management Group Inc., and NorthStar Realty Finance Corp. in January 2017. Colony NorthStar has significant property holdings in the healthcare, industrial, and hospitality sectors, other equity and debt investments and an embedded institutional and retail investment management business. Its current AUM is approximately $56 billion.

NorthStar I and NorthStar II are public, non-traded REITs financed by Colony NorthStar. NorthStar I and NorthStar II were formed to originate, acquire, and asset manage a diversified portfolio of commercial real estate debt, select equity, and securities investments in the US.

Last Close Stock Review

On Tuesday, August 29, 2017, the stock closed the trading session at $12.77, dropping 1.39% from its previous closing price of $12.95. A total volume of 2.16 million shares have exchanged hands. Colony NorthStar’s stock price surged 14.25% in the previous twelve months. The stock is trading at a PE ratio of 140.33 and has a dividend yield of 8.46%. At Tuesday’s closing price, the stock’s net capitalization stands at $7.03 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474161

Research Desk Line-up: Axovant Sciences Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) (“AVEO”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AVEO. The Company announced on August 28, 2017, the approval of FOTIVDA® (tivozanib) by European Commission (EC) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union (EU), also in Norway and Iceland. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Axovant Sciences Ltd (NYSE: AXON) for due-diligence and potential coverage as the Company announced on August 07, 2017, its financial results for fiscal Q1 which ended on June 30, 2017, as well as general business updates. Tune in to our site to register for a free membership, and be among the early birds that get our report on Axovant Sciences when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on AVEO; also brushing on AXON. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=AVEO

http://protraderdaily.com/optin/?symbol=AXON

Tivozanib is indicated for the first line treatment of adult patients with advanced RCC and who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve, following disease progression after one prior treatment with cytokine therapy for advanced RCC.

EUSA Pharma, a specialty pharmaceutical company, is the European licensee for tivozanib. The Company intends to work with the necessary health authorities to make tivozanib available to advanced RCC patients across Europe as quickly as possible.

AVEO Announced Positive CHMP Opinion for Tivozanib as a Treatment of Advanced RCC in June 2017

The approval from the EC follows the recommendation from the Committee for Medical Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA). On June 23, 2017, AVEO announced the recommendation of tivozanib by CHMP for approval as a treatment for patients with advanced RCC.

The decision was primarily based on data from a global, open-label, randomized, multi-center Phase-3 trial (TIVO-1) which evaluated the efficacy and tolerability of tivozanib compared to a currently available comparator VEGFR-TKI treatment (sorafenib) in 517 patients with advanced RCC. Results indicated that patients treated with tivozanib experienced superior Progression Free Survival (PFS) versus sorafenib, with an improved side effect profile with tivozanib. Additionally, fewer people on tivozanib experienced burdensome side effects.

European Approval Provides AVEO the Opportunity to Achieve Multiple Potential Commercial Milestone Payments

Michael Bailey, President and CEO of AVEO, expressed his happiness upon the availability of tivozanib for patients in Europe. He stated that the EC’s decision is the first regulatory approval of tivozanib globally, and a tremendous accomplishment for AVEO and its partner, EUSA Pharma. AVEO also continues to make progress on the next two pillars in its tivozanib strategy: US registration, driven by the pivotal Phase-3 TIVO-3 trial, and immunotherapy combination trials, starting with the TiNivo trial, Opdivo® combination trial. Michael further commented that European approval further strengthens the balance sheet by triggering an R&D payment to AVEO and provides AVEO the opportunity to achieve multiple potential commercial milestone payments, as well as royalty payments on sales, that would support the Company’s execution of the tivozanib strategy.

Licensing of Tivozanib Crucial in Expanding Treatment Options for RCC Patients in Europe

Commenting on the approval, Dr Jon Morgan, Medical Director at EUSA Pharma, mentioned that the licensing of tivozanib by the EC is an important step in expanding treatment options for patients with advanced RCC, where, despite advancements in therapy, survival rates in advanced disease remain low. The licensing of tivozanib is supported by results from the TiVO-1 pivotal study which demonstrated efficacy of tivozanib as a first-line treatment.

AVEO Oncology Awarded EUSA Pharma European Rights to Tivozanib in December 2015

The News release suggests that on December 21, 2015, AVEO Oncology granted EUSA Pharma European rights to tivozanib for advanced RCC, pursuant to which, EUSA Pharma holds exclusive commercialization rights to tivozanib in RCC in Europe and in a number of other territories outside North America, including South America and South Africa. AVEO retains the rights to commercialize the product in North America.

Under terms of the agreement, EUSA Pharma would pay AVEO an upfront research and development funding payment of $2.5 million, and up to $394 million in potential payments and milestones, assuming successful achievement of specified development, regulatory, and commercialization objectives, as well as a tiered royalty ranging from a low double-digit up to mid-twenty percent on net sales of tivozanib in the agreement’s territories.

About Tivozanib and RCC

Tivozanib, discovered by Kyowa Hakko Kirin, is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). Tivozanib has been investigated in several tumors types, including renal cell, colorectal and breast cancers. It is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications.

RCC is the most common form of kidney cancer, accounting for 80% of total kidney cancer cases in Europe, and an estimated 49,000 deaths each year. Tyrosine Kinase Inhibitor (TKI) vascular endothelial growth factor (VEGF) inhibitors are the standard of care treatment for advanced RCC in Europe, however, patients on current treatments can often experience significant side effects.

Last Close Stock Review

At the closing bell, on Tuesday, August 29, 2017, AVEO Pharma’s stock tumbled 12.24%, ending the trading session at $3.37. A total volume of 15.77 million shares have exchanged hands, which was higher than the 3-month average volume of 6.99 million shares. The Company’s stock price soared 374.65% in the last three months, 290.95% in the past six months, and 249.19% in the previous twelve months. Moreover, the stock skyrocketed 524.07% since the start of the year. The stock currently has a market cap of $367.23 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474159

Research Desk Line-up: Sanderson Farms Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Blue Buffalo Pet Products, Inc. (NASDAQ: BUFF) (“Blue Buffalo”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=BUFF, following the Company’s posting of its financial results on August 08, 2017, for the second quarter of the fiscal year 2017. The Company’s total revenue increased 2.8% on a y-o-y basis. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Food – Major Diversified industry. Pro-TD has currently selected Sanderson Farms, Inc. (NASDAQ: SAFM) for due-diligence and potential coverage as the Company reported on August 24, 2017, its financial results for Q3 FY17 which ended on July 31, 2017. Register for a free membership today, and be among the early birds that get access to our report on Sanderson Farms when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on BUFF; also brushing on SAFM. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=BUFF

http://protraderdaily.com/optin/?symbol=SAFM

Earnings Reviewed

For the three months ended June 30, 2017, Blue Buffalo’s total revenue increased 2.8% to $294.83 million on a y-o-y basis from $286.85 million in Q2 FY16. The increase was mainly due to a favorable product mix. During Q2 FY17, the Company’s Dry Foods segment’s revenue increased 3.3% to $237.5 million on a y-o-y basis and Wet Foods, Treats, and Other Products segment’s revenue increased 0.7% to $57.3 million on a y-o-y basis. The total revenue was below analysts’ expectations of $302.5 million.

During Q2 FY17, Blue Buffalo’s gross profit increased 8.2% to $137.74 million from $127.30 million in Q2 FY16. The increase was primarily due to supply chain efficiencies including lower input costs. For the reported quarter, the Company’s gross margin increased 230 basis points to 46.7% of revenue from 44.4% of revenue in Q2 FY16.

For the reported quarter, the Company’s selling, general, and administrative expenses (SG&A) increased 5.8% to $69.42 million from $65.60 million in Q2 FY16.

During Q2 FY17, Blue Buffalo’s earnings before interest, tax, depreciation, and amortization (EBITDA) increased 10.8% to $70.8 million from $63.9 million in Q2 FY16. For the reported quarter, the Company’s adjusted EBITDA increased 5.1% to $71.8 million from $68.3 million in Q2 FY16.

During Q2 FY17, Blue Buffalo’s operating income increased 10.7% to $68.31 million from $61.70 million in the same quarter of last year. During Q2 FY17, the Company’s operating margin increased 170 basis points to 23.2% of revenue from 21.5% of revenue in Q2 FY16. For the reported quarter, the Company’s adjusted operating margin increased 80 basis points to 23.2% of revenue from 22.4% of revenue in Q2 FY16.

During Q2 FY17, Blue Buffalo’s net income increased 16.5% to $42.68 million on a y-o-y basis from $36.62 million in Q2 FY16. During Q2 FY17, the Company’s adjusted net income increased 11.5% to $42.7 million on a y-o-y basis from $38.3 million in Q2 FY16. For the reported quarter, the Company’s diluted earnings per share (EPS) increased 16.7% to $0.21 on a y-o-y basis from $0.18 in Q2 FY16. During Q2 FY17, the Company’s adjusted diluted EPS increased 10.5% to $0.21 on a y-o-y basis from $0.19 in Q2 FY16. The adjusted diluted EPS was in-line with analysts’ expectations of $0.21.

Balance Sheet

As on June 30, 2017, Blue Buffalo’s cash and cash equivalents increased 15.7% to $338.73 million from $292.66 million in Q4 FY16.

During Q2 FY17, the Company’s inventories increased 26.2% to $89.53 million from $70.94 million in Q4 FY16. During Q2 FY17, Blue Buffalo’s accounts payable increased 45.9% to $51.41 million from $35.24 million in Q4 FY16.

For the reported quarter, the Company’s long-term debt increased 3.2% to $391.62 million from $379.18 million in Q4 FY16. During H1 FY17, Blue Buffalo’s cash provided by operating activities increased 15.4% to $63.04 million from $54.65 million in H1 FY16.

Outlook

For FY17, Blue Buffalo expects revenue to be in the range of $1.24 billion – $1.27 billion and estimates adjusted diluted EPS to be in the band of $0.91 – $0.94.

On July 31, 2017, the Company’s Board of Directors approved a $50 million share repurchase program, which the Company expects to complete in the fiscal year 2017.

Stock Performance

On Tuesday, August 29, 2017, the stock closed the trading session at $25.68, slightly up 0.31% from its previous closing price of $25.60. A total volume of 1.20 million shares have exchanged hands. Blue Buffalo Pet Products’ stock price surged 14.80% in the last one month, 9.32% in the past three months, and 3.88% in the previous six months. Furthermore, since the start of the year, shares of the Company have gained 6.82%. The stock is trading at a PE ratio of 35.72 and currently has a market cap of $5.08 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 474160